Amgen Inc. (AMGN) Revenue by Segment
Amgen revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Amgen's largest product or service was Other Products, with $1.70 billion or 17% of revenue, up 23.0% from a year earlier. Next: Repatha (evolocumab) (9%), Prolia (8%) and Evenity (7%).
The fastest-growing product or service from a year earlier was Evenity (+37.8%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2017.
Amgen Inc.
AMGN
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
Amgen revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Other Products | $1.7B | $1.5B | $1.9B | $1.4B | 17% |
| Repatha (evolocumab) | $953.0M | $876.0M | $794.0M | $696.0M | 9% |
| Prolia | $759.0M | $727.0M | $1.1B | $1.1B | 8% |
| Evenity | $714.0M | $562.0M | $541.0M | $518.0M | 7% |
| Enbrel | $580.0M | $320.0M | $580.0M | $604.0M | 6% |
| Tepezza | $576.0M | $490.0M | $560.0M | $505.0M | 6% |
| Other | $517.0M | $400.0M | $420.0M | $408.0M | 5% |
| Otezla | $491.0M | $431.0M | $585.0M | $618.0M | 5% |
| Tezspire | $486.0M | $343.0M | $377.0M | $342.0M | 5% |
| Blincyto | $472.0M | $415.0M | $392.0M | $384.0M | 5% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Amgen?
Other Products: $1.70 billion, or 17% of revenue, in Q2 fiscal 2026.
What are Amgen's main products and services?
By revenue in Q2 fiscal 2026: Other Products (17%), Repatha (evolocumab) (9%), Prolia (8%) and Evenity (7%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
